---
schema_version: "secwatch.filing_event.v1"
accession: "0001665988-26-000029"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2026-05-21T20:58:18+00:00"
generated_at: "2026-05-21T21:01:18.775768+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Bioventus Exogen device reclassified by FDA, CMS updates reimbursement rates; company reiterates 2026 guidance

## Summary
- FDA reclassified non-invasive bone growth stimulators, including Bioventus' Exogen Ultrasound Bone Healing System, from Class III to Class II on April 16, 2026.
- CMS updated Medicare fee schedule for HCPCS codes E0747, E0748, and E0760 for services on or after May 18, 2026.
- Bioventus does not expect material impact from reimbursement rate changes on its FY2026 financial results.
- Company reiterates previously issued 2026 financial guidance despite the regulatory changes.
- Bioventus continues to evaluate long-term impact; future CMS actions could require revised outlook.

## SEC filing metadata
- accession: 0001665988-26-000029
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2026-05-21T20:58:18+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000166598826000029/0001665988-26-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000166598826000029/bvs-20260521.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001665988-26-000029
- JSON: https://secwatch.observer/filing/0001665988-26-000029.json
- Plain text: https://secwatch.observer/filing/0001665988-26-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.